GlobeNewswire

NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
19/03/2026
Conference call will be held today, Thursday, March 19 at 9:00 am ET CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company [...]
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026
19/03/2026
WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host a [...]
Asimov Launches RNA Edge, a Lab-in-the-Loop Platform for AI Optimization of RNA Therapeutic Candidates
19/03/2026
End-to-end RNA optimization: Platform combines proprietary AI sequence optimization, novel genetic parts, and lab validation in application-relevant cell models to improve expression and half-life, delivering top [...]
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
19/03/2026
Preclinical results in therapy-resistant HER2-low breast cancer models demonstrate enhanced antitumor activity and reversal of resistance with PLK1 inhibition SAN DIEGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cardiff [...]
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
19/03/2026
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain [...]
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
19/03/2026
Breakthrough Therapy Designation granted to nomlabofusp for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label study Continued alignment with FDA to consider [...]
Aveanna Healthcare Holdings Announces Fourth Quarter and Full Year 2025 Financial Results
19/03/2026
Fourth Quarter Revenue was $662.5 million, a 27.4% increase over the prior year period Fourth Quarter Net income was $178.8 million compared to $29.2 million for the prior year period Adjusted EBITDA for Q4 2025 was $85 [...]
Tilray Medical Announces Major Expansion of Medical Cannabis Portfolio in Australia
19/03/2026
NEW YORK and SYDNEY, March 19, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), today announced its [...]
NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference
19/03/2026
Results illustrate how NetraMark’s advanced AI can potentially support precision enrichment strategies in future trials TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark [...]
Remix Therapeutics Granted FDA Fast Track Designation for REM-422 for the Treatment of Recurrent, Metastatic or Unresectable Adenoid Cystic Carcinoma
19/03/2026
Preliminary Phase 1 Study Results Show Strong Anti-Tumor Activity and Favorable Safety Profile for First-in-Class Small Molecule MYB mRNA Degrader No Approved Treatment Options for Patients with MYB-Driven Solid Tumor [...]
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026
19/03/2026
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PD TM 2026 Initial data indicates significantly higher tracer uptake in patients with genetically [...]
Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results
19/03/2026
ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total [...]
Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01
19/03/2026
STAFFORD, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts
19/03/2026
Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 Strong Balance Sheet with [...]
Priavoid Presents Preclinical Proof-of-Concept for PRI-101 Demonstrating α-synuclein Aggregate Disassembly at AD/PD™ 2026
19/03/2026
PRI-101 inhibited aggregation of α-synuclein and actively disassembled fibrils across in vitro and in vivo models relevant to Parkinson’s disease Dusseldorf, Germany, March 19, 2026 - Priavoid GmbH (“Priavoid”) today [...]
BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair
19/03/2026
Seasoned life science investor, executive and board leader to support next phase of growth as BOOST Pharma advances BT-101, a promising and potentially disease-modifying therapy for osteogenesis imperfecta STOCKHOLM, [...]
SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment
19/03/2026
RANCHO CORDOVA, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector business, while reaffirming its long-term [...]
Persica Pharmaceutical’s PP353 Phase 1b Data Selected for Oral Presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting
19/03/2026
ASIPP presentation follows publication of positive data from PP353 Phase 1b Modic Trial in The Lancet’s eClinicalMedicine London, UK, 19 March 2026 - Persica Pharmaceuticals Limited (Persica), a clinical stage [...]
Roquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environment
19/03/2026
Roquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environment The Group’s strategy and recent acquisitions enable upselling to higher-value markets +8% turnover growth to € [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum